NCT02541344View on ClinicalTrials.gov

Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

October 31, 2015

Conditions
PrediabetesHyperglycemia
Interventions
DEVICE

Dose 1 of IQP-VV-102

Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.

DEVICE

Dose 2 of IQP-VV-102

Dose 2 (D2) group will take 4 tablets with active ingredients.

DEVICE

Placebo

"Placebo group will take 4 placebo tablets.~The placebo is designed to be identical to IQP-VV-102."

Trial Locations (1)

10369

analyze & realize GmbH, Berlin

Sponsors

Lead Sponsor

InQpharm Group
All Listed Sponsors
lead

InQpharm Group

INDUSTRY